New treatments for pulmonary arterial hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 165, Issue 9, 2002, Pages 1209-1216

  Hoeper, Marius M ^a,b,c,d   Galiè, Nazzareno ^a,b,c,d   Simonneau, Gerald ^a,b,c,d   Rubin, Lewis J ^a,b,c,d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c HÔPITAL ANTOINE BÉCLÈRE   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BERAPROST; BONE MORPHOGENETIC PROTEIN RECEPTOR; BOSENTAN; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN; SILDENAFIL; SITAXSENTAN; TOLAFENTRINE; TRANSFORMING GROWTH FACTOR ALPHA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; UNCLASSIFIED DRUG; UNIPROST;

ANGIOGENESIS; CLINICAL TRIAL; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; DRUG TOLERANCE; HEADACHE; HUMAN; NAUSEA; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW;

ARGININE; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PROSTAGLANDINS; RECEPTORS, ENDOTHELIN; VASODILATOR AGENTS;

EID: 0036569895     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200110-028PP     Document Type: Review

References (106)

1. Primary pulmonary hypertension
2. Pulmonary hypertension
3. Role of atrioseptostomy in the treatment of pulmonary vascular disease
4. Primary pulmonary hypertension: A vascular biology and translational research work in progress
5. Nitric oxide and endothelin-1 in pulmonary hypertension
6. Reduced expression of the endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension
7. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension
8. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
9. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension
10. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension
11. A new era in the treatment of primary pulmonary hypertension
12. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension
13. Plexiform lesions in primary pulmonary hypertension may represent an abnormal form of angiogenesis
14. Distribution of obstructive intimal lesions and their cellular phenotype in chronic pulmonary hypertension
15. Vascular smooth muscle cell phenotypes in primary pulmonary hypertension
16. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension
17. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers
18. Primary pulmonary hypertension between inflammation and cancer
19. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: Evidence for a process of disordered angiogenesis
20. Vascular endothelial growth factor in pulmonary hypertension
21. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension
22. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension
23. Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and in rat lungs via cAMP
24. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred
25. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension
26. Familial primary pulmonary hypertension (gene PPH-1) is caused by mutations in the bone morphogenetic protein receptor-II gene
27. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family
28. Severe pulmonary hypertension after the discovery of the familial primary pulmonary hypertension gene
29. Altered growth response of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-β1 and bone morphogenetic proteins
30. Genetic clues to the cause of primary pulmonary hypertension
31. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension
32. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension
33. + channel gene transcription in primary pulmonary hypertension
34. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension
35. Linking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertension
36. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
37. How effective is the treatment with high-dose nifedipine for primary pulmonary hypertension?
38. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)
39. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades
40. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery
41. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients
42. Prostaglandins prevent inducible nitric oxide synthase protein expression by inhibiting nuclear factor-κB activation in J774 macrophages
43. 2 analogue, iloprost, down regulates mitogen-activated protein kinases of macrophages
44. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
45. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
46. Primary pulmonary hypertension: Improved long-term effects and survival with continuous intravenous epoprostenol infusion
47. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension
48. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease
49. Systemic sclerosis-associated pulmonary hypertension: Short- and long-term effects of epoprostenol (prostacyclin)
50. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: Results of a pilot study
51. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus
52. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension
53. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects
54. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: A case series
55. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension
56. Iloprost: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischemia and extracorporeal circulation procedures
57. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost
58. The effects of I5AU8I, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensin systems of anesthetized dogs
59. Continuos subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind randomized controlled trial
60. Improvement of exercise tolerance due to uniprost in patients with pulmonary arterial hypertension is related to baseline performance
61. 2 analogue, beraprost, in primary and secondary pulmonary hypertension
62. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension
63. Effect of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomised, double-blind, placebo-controlled trial
64. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension
65. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension
66. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension
67. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension
68. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial
69. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue
70. Long-trem treatment of pulmonary hypertension with aerosolized iloprost
71. Prolongation of prostanoid inhalation-induced pulmonary vasodilation by concomitant PDE-3/4 inhibition in patients with severe pulmonary hypertension
72. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension
73. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease?
74. Endothelins and endothelin receptor antagonists: Therapeutic considerations for a novel class of cardiovascular drugs
75. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension
76. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study
77. Bosentan in patients with pulmonary artery hypertension: A randomized, placebo controlled, multicenter study
78. Efficacy and safety of chronic treatment with the oral selective endothelin-A receptor blocker sitaxsentan in pulmonary arterial hypertension (PAH)
79. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange
80. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension
81. Sildenafil modulates hemodynamics and pulmonary gas exchange
82. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension
83. Use of sildenafil (Viagra) in patients with cardiovascular disease
84. Sildenafil in primary pulmonary hypertension
85. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension
86. Oral sildenafil in the treatment of erectile dysfunction
87. Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the γ-subunit of phosphodiesterase
88. Improvement in exercise capacity with nitric oxide inhalation in patients with precapillary pulmonary hypertension
89. The L-arginine-nitric oxide pathway
90. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension
91. Differential systemic and pulmonary hemodynamic effects of L-arginine in patients with coronary artery disease or primary pulmonary hypertension
92. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension
93. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
94. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension
95. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension
96. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost
97. 2 analogue: Prolongation by PEGylation
98. Viagra for impotence of pulmonary vasodilator therapy
99. Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats
100. 40-O-(2-Hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats
101. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor
102. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease
103. Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis
104. Cell-based gene transfer to the pulmonary vasculature: Endothelial nitric oxide synthase over-expression inhibits monocrotaline-induced pulmonary hypertension
105. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension